affymetrix inc (AFFX) Key Developments
Affymetrix Inc. and BioDiscovery, Inc. Launches New Analysis Software, Nexus Copy Number
Jun 5 14
Affymetrix and BioDiscovery, Inc. announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan(R) Cytogenetics Suite and OncoScan(R) FFPE Assay Kit. CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of Affymetrix cancer portfolio. Researchers have been finding CNVs and copy neutral changes in liquid and solid tumor samples. With the use of Nexus Copy Number, an advanced discovery tool for interrogating large data sets, researchers have been able to identify biomarkers that drive disease progression. The new Nexus Copy Number for Affymetrix software offers researchers a version of the Nexus Copy Number software that is easier to access and has been specifically tailored for Affymetrix' assays.
Affymetrix Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 11:00 AM
May 22 14
Affymetrix Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 11:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Franklin R. Witney, Chief Executive Officer, President and Director, Gavin H. J. Wood, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.
Affymetrix Inc. and Leica Biosystems Announce Launch of Fully Automated RNA in situ Hybridization Assays
May 8 14
Affymetrix Inc. and Leica Biosystems announced the launch of Affymetrix' fully automated RNA in situ hybridization assays ViewRNA(TM) eZ Assays on the Leica BOND RX staining platform. These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues. Dedicated for research use only, the assays provide researchers with a powerful automated solution for drug discovery, translational research, and the development of new diagnostic tests for personalized medicine. The automation significantly reduces hands-on time and assay run time for profiling single-cell gene expression. The Leica BOND RX system automates the staining process, bringing all the benefits of consistency, reduced labor, and speed. This fully automated assay is hands-free from tissue de-waxing to counter staining, and offers high sensitivity, specificity, and reproducibility with easy standardization across laboratories. ViewRNA eZ Assays represent a major technological advancement offering a robust and reliable platform to easily interrogate the function and disease relevance of any expressed genes. Affymetrix' ViewRNA eZ Assays on the Leica BOND RX platform are now available for research applications. The ViewRNA eZ staining protocol is pre-loaded onto the Leica BOND RX, and the staining kit optimized for FFPE samples and probes of choice are available from Affymetrix.
Affymetrix Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014
May 1 14
Affymetrix Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net loss of $10,474,000 or $0.14 per basic and diluted share on total revenue of $82,971,000 compared to net loss of $15,437,000 or $0.22 per basic and diluted share on total revenue of $77,945,000 reported a year ago. Loss from operations was $8,742,000 compared to $12,206,000 for the same period of last year. Loss before income taxes was $10,202,000 compared to $14,762,000 for the same period of last year. Non-GAAP net income was $1,904,000 or $0.03 per basic and diluted share compared to non-GAAP net loss of $856,000 or $0.01 per basic and diluted share reported a year ago.
Enzo Biochem Announces Settlement Agreement with Affymetrix
Apr 24 14
Enzo Biochem Inc. along with its subsidiary Enzo Life Sciences Inc. entered into a settlement with Affymetrix Inc. with respect to actions between the company and Affymetrix before the U.S. District Court, Southern District of New York, Cases No 03-CV-8907 and 04-CV-1555. As a result of the Agreement in settlement of the cases, Affymetrix will pay $5,100,000. Enzo's release of Affymetrix Inc. does not include the litigation currently pending against Affymetrix Inc. in the District of Delaware and any of the claims there asserted.